Cytophage Technologies (TSXV:CYTO) ROCE % : 377.64% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cytophage Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was 377.64%.

Cytophage Technologies ROCE % Historical Data

The historical data trend for Cytophage Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies ROCE % Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-56.64

-16.46

-3.07

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
ROCE %	-	-38.95	239.51	-161.63	377.64

Cytophage Technologies ROCE % Calculation

Cytophage Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.136	/	( ( (3.69 - 0.238)	+	(5.461 - 0.049) )	/ 2 )
	=	-0.136	/	( (3.452	+	5.412)	/ 2 )
	=	-0.136	/	4.432
	=	-3.07 %

Cytophage Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	12.804	/	( ( (1.612 - 0.243)	+	(5.461 - 0.049) )	/ 2 )
	=	12.804	/	( ( 1.369	+	5.412 )	/ 2 )
	=	12.804	/	3.3905
	=	377.64 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cytophage Technologies (TSXV:CYTO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cytophage Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.